Soleno Therapeutics announces proposed $200M public offering

Soleno Therapeutics (SLNO) intends to offer and sell $200M of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30M of shares of common stock. The proposed public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. and Guggenheim Securities are acting as the joint book-running managers for the proposed public offering. Soleno intends to use the net proceeds from this offering to fund the commercialization of VYKAT XR. Soleno also intends to use the proceeds from the public offering to fund its regulatory and market development activities in the European Union and further research and development efforts, as well as general corporate purposes.